Review Papers Claim by Claim

Concise verdict

This 1995 Neurology study (n=11 DMD boys vs n=8 controls) measured tibialis anterior force, CMAP, twitch/tetanus and a 4-minute sustained MVC with superimposed stimuli. It found: (1) lower absolute forces and CMAP in DMD consistent with reduced muscle mass, (2) similar electrically‑evoked intramuscular fatigability (TT/TF) and recovery between groups, and (3) much smaller increase in added force (an index of central fatigue) in DMD — likely confounded by unequal prior practice/training and cyclosporine exposure in patients, small n, and single‑muscle scope, so conclusions about central fatigue should be treated cautiously.Sharma et al., Muscular fatigue in DMD (1995)

Visual paper review — "Muscular fatigue in Duchenne muscular dystrophy" (Sharma et al., Neurology 1995)

Critical appraisal — strengths

• Well‑defined physiological protocol using standard electrophysiology (CMAP, twitch/tetanus, MVC) and superimposed stimulation allowing separation of central vs peripheral contributors to force loss — a robust approach for the question posed.Sharma et al., methods
• Molecular confirmation of dystrophin deficiency ensured a homogeneous DMD cohort (reduces genotype‑mixing bias common in older studies).

Critical appraisal — limitations & biases

• Small sample size (n=11 vs n=8) strongly limits power and increases vulnerability to Type I/II errors and idiosyncratic effects; external validity across ages, muscles, and disease stages is limited.Sharma et al., sample size
• Major confounder: 10/11 DMD patients received cyclosporine for 7–13 days before testing (stated as immunosuppression for subsequent myoblast implantation). Cyclosporine can affect neuromuscular physiology and central nervous system function; this exposure complicates interpretation of reduced central fatigue in patients.Sharma et al., cyclosporine use
  (Note: later literature documents cyclosporine effects on mitochondrial function and possible central side effects — a potential confound not discussed in the manuscript.)
• Practice/training imbalance: patients had multiple prior monthly isometric testing sessions while controls had only a brief practice — this can reduce observed central fatigue in the familiar group, plausibly explaining much of the added‑force difference rather than a disease biology effect.Sharma et al., practice effect
• Single-muscle focus (tibialis anterior) — results may not generalize to other muscles with different fiber composition or loading (e.g., diaphragm, quadriceps). Animal and human studies show heterogeneity of fatigability across muscles and models of dystrophy.Sharma et al., muscle specificity
• No public data deposition or detail for full numeric series (e.g., per-minute MVC/TF/TT values) — reduces reproducibility and meta‑analytic reuse.

Context with later literature — where this fits

Sharma et al. (1995) sits in a body of mixed findings about fatigue in dystrophinopathies: some human studies find similar intramuscular fatigability but altered central contributions; mechanistic work has since emphasized metabolic remodeling, altered mitochondrial dynamics, and nNOS mislocalization as contributors to exercise intolerance and fatigue in dystrophin-deficient muscle (animal and human work) — these mechanisms were not testable in the 1995 protocol and may explain heterogeneous fatigability across muscles and protocols.

• Metabolic / mitochondrial remodeling in dystrophic muscle (mouse DKO) shows increased oxygen use per force and altered fatigue properties — suggests metabolic contributors to fatigability beyond pure contractile apparatus changes.Spaulding et al., metabolic remodeling in DKO mice
• nNOS loss from the sarcolemma is linked to increased fatigue in muscular dystrophies and is a therapeutic target considered in later human/biopsy studies — this axis was not measured in 1995 but is highly relevant to interpreting fatigue mechanisms in DMD.
• Clinical/rehabilitation literature recommends multifactorial fatigue evaluation in neuromuscular disease because central and peripheral contributions interact with cardiopulmonary and psychosocial factors; single-test paradigms may misattribute cause without controlling for these factors.Moussavi et al., fatigue in NMD review

Bottom-line interpretation (evidence-weighted)

1. Strong/robust: DMD tibialis anterior in this cohort had lower baseline force and CMAP consistent with reduced muscle mass/fiber number — the data support a peripheral (loss of contractile mass) explanation for lower absolute force.Sharma et al., baseline deficits conclusion
2. Moderate/uncertain: Intramuscular fatigability (electrically evoked TF and TT changes) appears similar between groups under this sustained MVC protocol — but this conclusion is limited to tibialis anterior and to the specific protocol and n, and does not exclude muscle-specific or metabolic differences revealed by later models.
3. Weak/ambiguous: The finding of reduced central fatigue (smaller added force increase) in DMD is likely confounded (practice/training imbalance, cyclosporine exposure) and should not be taken as definitive evidence that DMD patients have superior central activation; a controlled, randomized protocol with matched familiarization is needed to support such a claim.

What would change the conclusion (falsification tests)

• If a larger, independent, well‑balanced cohort (matched familiarization, no peri-testing immunosuppression) showed significantly greater intramuscular fatigue (larger TF/TT decline or CMAP decrement) in DMD vs controls under identical protocols, the conclusion that intramuscular fatigability is similar would be falsified.
• If matched-practice controls replicate the small added-force difference (DMD << controls) without pharmacologic confounders, then the central-fatigue interpretation would gain credibility.
• Direct measures of metabolic state (31P‑MRS), mitochondrial function, or nNOS localization in the same subjects during/after identical fatigue protocols would test whether metabolic or signaling defects alter fatigability beyond contractile mass effects (contradicting a purely mass‑based explanation).

Suggested improvements / next experiments

• Repeat protocol with larger N, matched familiarization (identical practice exposures for patients and controls), and without peri‑testing immunomodulators; include multiple muscles (tibialis anterior, quadriceps, diaphragm if possible).
• Add metabolic and membrane assays during exercise: 31P‑MRS for high‑energy phosphates/pH, muscle biopsy or noninvasive measures for nNOS/sarcoplasmic reticulum function, and mitochondrial biomarkers to detect metabolic contributors to fatigue (connects to mouse DKO findings of metabolic remodeling).DKO metabolic study relevance